A compound originally developed as a cancer treatment may hold promise for treating polycystic kidney disease (ADPKD), which affects more than half a million Americans and can lead to kidney ...
Their results indicated that deletion of the binding site increased stability of the mRNA strand, raised Polycystin-1 levels, and decreased kidney cyst growth. Moreover, the group found that blocking ...
Polycystic kidney disease (PKD) is a debilitating hereditary condition in which fluid-filled sacs form and proliferate in the kidneys. Over time, the painful, growing cysts rob the organs of their ...
A prolonged course of antibiotic therapy dramatically reduces the risk of recurrence in patients with renal cyst infections in the context of autosomal dominant polycystic kidney disease (ADPKD), a ...
Polycystic kidney disease (PKD) is a genetic disorder marked by the growth of many fluid-filled sacs (cysts) in your kidneys. These cysts can grow to replace normal kidney tissue over time, leading to ...
Polycystic kidney disease (PKD) is a debilitating hereditary condition in which fluid-filled sacs form and proliferate in the kidneys. Over time, the painful, growing cysts rob the organs of their ...
A research project has successfully reproduced the pathogenesis of autosomal dominant polycystic kidney disease (ADPKD) from human iPS cells in vitro. Although cysts derived from renal tubules have ...
MIT researchers including Robert Croy (left) and Bogdan Fedeles have discovered that a drug they originally developed as a potential cancer treatment may also hold promise in treating autosomal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results